Adaptimmune Therapeutics PLC
NASDAQ:ADAP

Watchlist Manager
Adaptimmune Therapeutics PLC Logo
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Watchlist
Price: 0.04 USD Market Closed
Market Cap: 10.6m USD

Wall Street
Price Targets

ADAP Price Targets Summary
Adaptimmune Therapeutics PLC

There are no price targets for ADAP.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Adaptimmune Therapeutics PLC Competitors:
Price Targets
PRME
Prime Medicine Inc
75% Upside
1801
Innovent Biologics Inc
31% Upside
KALV
Kalvista Pharmaceuticals Inc
100% Upside
302440
SK Bioscience Co Ltd
23% Downside
KNSA
Kiniksa Pharmaceuticals Ltd
27% Upside
BAVA
Bavarian Nordic A/S
34% Upside
SYNACT
SynAct Pharma AB
20% Upside
CRBU
Caribou Biosciences Inc
575% Upside

Revenue
Forecast

Revenue Estimate
Adaptimmune Therapeutics PLC

For the last 11 years the compound annual growth rate for Adaptimmune Therapeutics PLC's revenue is 68%. The projected CAGR for the next 4 years is 9%.

68%
Past Growth
9%
Estimated Growth
Estimates Accuracy
-6%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Adaptimmune Therapeutics PLC

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Net Income
Forecast

Net Income Estimate
Adaptimmune Therapeutics PLC

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-47%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ADAP's stock price target?
Not Available

ADAP doesn't have any price targets made by Wall Street professionals.

What is Adaptimmune Therapeutics PLC's Revenue forecast?
Projected CAGR
9%

For the last 11 years the compound annual growth rate for Adaptimmune Therapeutics PLC's revenue is 68%. The projected CAGR for the next 4 years is 9%.

Back to Top